Rocket Pharmaceuticals Inc (NAS:RCKT)
$ 22.23 0.3 (1.37%) Market Cap: 2.02 Bil Enterprise Value: 1.69 Bil PE Ratio: 0 PB Ratio: 4.56 GF Score: 39/100

Rocket Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 07:30PM GMT
Release Date Price: $13.91 (-13.44%)
Jason Russell
Morgan Stanley - MD

Okay. Great. Thanks, everyone, for joining. To the research disclosure first. So, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep.

Gaurav, thanks for joining us. So, Jason Russell with the health care banking team. Really pleased to be here with Dr. Gaurav Shah, CEO of Rocket Pharma. So, I'd just like to jump right in.

Start with the layup. I knew the company when you first started, few lentiviral gene therapy programs. Company has obviously evolved and emerged over time. So before we get to specific questions, just give us a little bit of context of founding of the company, evolution over these past 4 or 5 years, and we'll go from there.

Gaurav D. Shah
Rocket Pharmaceuticals, Inc. - CEO & Director

Jason, good to see you. Great to be here again this year

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot